View Older Stories View More Recent Stories

Aug 8, 2016 08:03AM Intrexon (XON) Names Andrew J. Last, Ph.D. COO
Aug 8, 2016 08:00AM Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer
Aug 4, 2016 08:01AM Fibrocell Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
Aug 2, 2016 08:00AM Intrexon to Announce Second Quarter and First Half 2016 Financial Results on August 9th
Jul 28, 2016 08:01AM Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
Jul 27, 2016 04:01PM Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Jul 25, 2016 08:00AM Intrexon Introduces Florian™ Switch Technology for Flowering Control
Jul 19, 2016 09:00AM Oxitec and Piracicaba City Hall Start Downtown Release of Friendly™ Aedes
Jul 14, 2016 09:03AM Intrexon (XON) Unit Announces Positive Results in Cutting Dengue Fever Utilizing Friendly Aedes
Jul 14, 2016 09:00AM Dengue Fever Cases Drop 91% in Neighbourhood of Piracicaba, Brazil, Where Oxitec's Friendly™ Aedes Were Released
Jul 7, 2016 04:05PM Fibrocell to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Jun 30, 2016 04:01PM Intrexon Appoints Fred Hassan, Distinguished Life Sciences Executive, to Board of Directors
Jun 30, 2016 08:03AM Ziopharm Oncology (ZIOP), Intrexon (XON) Enter Amended ECCs; Will Include Increased Investment
Jun 30, 2016 08:00AM Intrexon and ZIOPHARM Amend Exclusive Channel Collaborations to Improve Alignment as Programs Advance through Development
Jun 20, 2016 08:00AM Intrexon to Present at the JMP Securities Life Sciences Conference
Jun 13, 2016 08:04AM Fibrocell Science (FCSC) Commences Recruitment for FCX-007 Phase 1/2 as RDEB Treatment
Jun 13, 2016 08:00AM Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Jun 10, 2016 08:00AM Intrexon to Present at the Jefferies 2016 Healthcare Conference
Jun 8, 2016 05:08PM Intrexon's (XON) Oxitec Welcomes NASEM Report on Gene Drives
Jun 8, 2016 05:05PM Oxitec Supports the National Academies of Sciences, Engineering, and Medicine Recommendations on Gene-drive and Highlights Why Oxitec's Self-limiting Approach is the Opposite of Gene-drive Method
Jun 8, 2016 08:04AM Fibrocell Science (FCSC) Reports Azficel-T Phase 2 in Vocal Cord Scarring Missed Primary Endpoints
Jun 8, 2016 08:00AM Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
Jun 6, 2016 08:11AM Intrexon (XON) SVP/Head of Health Sector Samuel Broder to Retire
Jun 6, 2016 08:00AM Intrexon Announces Retirement of Samuel Broder, M.D., Head of Health Sector
May 31, 2016 02:03PM Intrexon's (XON) Oxitec Expands Vector Control Solution in Brazil
May 31, 2016 02:00PM Oxitec Expands Vector Control Solution in Brazil
May 23, 2016 08:00AM Intrexon to Present at Upcoming Investor and Industry Conferences
May 23, 2016 07:00AM Oxitec CEO to Testify Before Congressional Committee on May 25th
May 17, 2016 08:06AM Intrexon (XON) Names Geno Germano as President
May 17, 2016 08:00AM Intrexon Appoints Geno Germano to New Role of President
May 10, 2016 04:05PM Intrexon Announces First Quarter 2016 Financial Results
May 5, 2016 10:33AM Grand Cayman Will Use Oxitec Solution to Suppress Wild Aedes aegypti, the Dangerous Mosquito that Spreads Dengue, Zika and Chikungunya, in an Effort to Help Eliminate These Diseases
May 5, 2016 08:00AM Fibrocell Reports First Quarter 2016 Financial Results and Operational Highlights
May 4, 2016 08:30AM Intrexon Establishes Crop Protection Enterprise
Apr 28, 2016 08:00AM Intrexon to Announce First Quarter 2016 Financial Results on May 10th
Apr 27, 2016 10:37AM INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Intrexon Corporation and Advises Investors with Losses in Excess of $50,000 to Contact the Firm
Apr 27, 2016 09:28AM Pre-Open Stock Movers 04/27: (SPA) (DWA) (WNC) Higher; (DVAX) (TWTR) (BWLD) Lower (more...)
Apr 22, 2016 03:37PM IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Intrexon Corporation and Advises Investors With Losses to Contact the Firm
Apr 22, 2016 07:17AM Intrexon (XON) Says Short-Seller Report Includes Inaccurate Claims
Apr 22, 2016 07:15AM Intrexon Provides Update on Recent Stock Trading Activity
Apr 21, 2016 08:07AM Fibrocell Science (FCSC) Announces Final Patient Visit for Azficel-T Phase 2 Primary Endpoint (XON)
Apr 21, 2016 08:00AM Fibrocell Announces Last Patient Visit for Primary Endpoint Analysis in Phase II Clinical Trial of azficel-T for the Treatment of Vocal Cord Scarring
Apr 18, 2016 08:07AM Fibrocell Science (FCSC) Receives FDA Allowance to Commence FCX-007 Phase 1/2 in RDEB (XON)
Apr 18, 2016 08:00AM Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Apr 13, 2016 08:06AM Intrexon (XON) Enters ECCs with Two Harvest Intrexon Enterprise Fund-Backed Startups
Apr 13, 2016 08:00AM Intrexon Forms Two New Collaborations with Harvest Intrexon Enterprise Fund
Apr 4, 2016 08:00AM Intrexon Forms Collaboration to Develop Treatment for Type 1 Diabetes
Feb 25, 2016 04:02PM Forging a New Frontier in Protein Supply and Feed Sustainability
Feb 23, 2016 09:15AM Intrexon Expresses Support for Resident Commissioner of Puerto Rico's Statements on Combatting Aedes aegypti Mosquitoes in Puerto Rico and Other U.S. Jurisdictions
Jan 25, 2016 12:26PM Streetinsider.com's Hot Lunchtime Reads 1/25: (TWTR) (AAPL) (GSK) (MDLZ)
View More Recent Stories View Older Stories